Table 3.
Frequency of external and visceral malformations in fetuses from female rats administered KACY during days 6 through 15 of gestation.
| Groups (mg/kg) |
||||||
|---|---|---|---|---|---|---|
| Control | ASA 250 | KACY 50 | KACY 250 | KACY 500 | KACY 1000 | |
| External | ||||||
| Fetuses analyzed | 178 | 87 | 180 | 186 | 179 | 176 |
| Exencephaly | 0 (0%) | 26 (30%)a | 0 (0%)b | 0 (0%)b | 0 (0%)b | 0 (0%)b |
| Craniorachischisis | 0 (0%) | 13 (15%)a | 0 (0%)b | 0 (0%)b | 0 (0%)b | 0 (0%)b |
| Gastroschisis | 0 (0%) | 17 (20%)a | 0 (0%)b | 0 (0%)b | 0 (0%)b | 0 (0%)b |
| Kinked tail | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Visceral | ||||||
| Fetuses analyzed | 123 | 61 | 123 | 128 | 124 | 125 |
| Hydrocephalus | 0 (0%) | 17 (28%)a | 0 (0%)b | 0 (0%)b | 0 (0%)b | 0 (0%)b |
| Hydronephrosis | 0 (0%) | 7 (11%)a | 0 (0%)b | 0 (0%)b | 0 (0%)b | 0 (0%)b |
| Ectopic kidney | 0 (0%) | 2 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Values in parenthesis denote percentages. ASA = acetylsalicylic acid; KACY = kramecyne. Significant difference (p < 0.05) in relation to the acontrol, bASA at 250 mg/kg and/or cKACY at 1000 mg/kg.